Paid Clinical Trials Mississippi

Discover 380 paid clinical trials in Mississippi. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 380

Linezolid for Syphilis Pilot StudyLinezolid for Syphilis Pilot Study

Recruiting

PHASE2

Sponsor:

University of Southern California

Location:

Jackson MS, Chicago IL

Code:

NCT05548426

Conditions

Syphilis

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

Group B, Linezolid 10d

Group A, Penicillin

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Ridgeland MS, Flowood MS, Pensacola FL, Gulf Breeze FLshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Ridgeland MS, Fayette MS, Cordova TN, Memphis TNshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Grenada MS, Columbus MS, Oxford MS, New Albany MSshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Jackson MS, Memphis TN, Birmingham AL, New Orleans LAshow 103 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt DiseaseStudy to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease

Recruiting

PHASE1

PHASE2

Sponsor:

Ocugen

Location:

Jackson MS, Bellaire TX, Dallas TX, Durham NCshow 2 more

Code:

NCT05956626

Conditions

Stargardt Disease

Eligibility Criteria

Sex: All

Age: 6 - 65

Healthy Volunteers: Not accepted

Interventions

OCU410ST

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisStudy to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Recruiting

PHASE2

Sponsor:

Kowa Research Institute, Inc.

Location:

Flowood MS, Birmingham AL, Marrero LA, Little Rock ARshow 42 more

Code:

NCT05327127

Conditions

NASH

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

K-877-ER

CSG452

Placebo

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Hattiesburg MS, Monroe LA, New Orleans LA, Jackson TNshow 77 more

Code:

NCT05814627

Conditions

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Upadacitinib

Adalimumab

Upadacitinib Matching Placebo

Adalimumab Matching Placebo

Do AxoGuard Implants Decrease Shoulder Disability After Neck DissectionsDo AxoGuard Implants Decrease Shoulder Disability After Neck Dissections

Recruiting

Sponsor:

University of Mississippi Medical Center

Location:

Jackson MS

Code:

NCT03941327

Conditions

Spinal Accessory Nerve Injury

Cervical Lymphadenopathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AxoGuard Nerve Cuff

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

PHASE3

Sponsor:

Arcus Biosciences, Inc.

Location:

Hattiesburg MS, Baton Rouge LA, Atlanta GA, Dallas TXshow 20 more

Code:

NCT06608927

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Quemliclustat

Placebo

Nab-paclitaxel

Gemcitabine

Popular cities in Mississippi

Gulfport Hattiesburg Jackson